

# Epigenetic Silencing of the Tumor Suppressor MicroRNA *Hsa-miR-124a* Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia

Xabier Agirre,<sup>1</sup> Amaia Vilas-Zornoza,<sup>1</sup> Antonio Jiménez-Velasco,<sup>4</sup> José Ignacio Martín-Subero,<sup>5</sup> Lucia Cordeu,<sup>1</sup> Leire Gárate,<sup>1</sup> Edurne San José-Eneriz,<sup>1</sup> Gloria Abizanda,<sup>1</sup> Paula Rodríguez-Otero,<sup>1</sup> Puri Fortes,<sup>2</sup> José Rifón,<sup>1</sup> Eva Bandrés,<sup>1</sup> María José Calasanz,<sup>3</sup> Vanesa Martín,<sup>6</sup> Anabel Heiniger,<sup>4</sup> Antonio Torres,<sup>6</sup> Reiner Siebert,<sup>5</sup> José Román-Gomez,<sup>6</sup> and Felipe Prósper<sup>1</sup>

<sup>1</sup>Hematology Department and Area of Cell Therapy, Clínica Universitaria and <sup>2</sup>Division of Gene Therapy and Hepatology, Foundation for Applied Medical Research, and <sup>3</sup>Department of Genetics, University of Navarra, Pamplona, Spain; <sup>4</sup>Hematology Department, Carlos Haya Hospital, Malaga, Spain; <sup>5</sup>Institute of Human Genetics, University Hospital Schleswig-Holstein Campus Kiel/Christian-Albrechts University Kiel, Kiel, Germany; and <sup>6</sup>Hematology Department, Reina Sofia Hospital, Cordoba, Spain

## Abstract

Whereas transcriptional silencing of genes due to epigenetic mechanisms is one of the most important alterations in acute lymphoblastic leukemia (ALL), some recent studies indicate that DNA methylation contributes to down-regulation of miRNAs during tumorigenesis. To explore the epigenetic alterations of miRNAs in ALL, we analyzed the methylation and chromatin status of the *miR-124a* loci in ALL. Expression of *miR-124a* was down-regulated in ALL by hypermethylation of the promoter and histone modifications including decreased levels of 3mk4H3 and ACh3 and increased levels of 2mk9H3, 3mk9H3, and 3mk27H3. Epigenetic down-regulation of *miR-124a* induced an up-regulation of its target, *CDK6*, and phosphorylation of retinoblastoma (Rb) and contributed to the abnormal proliferation of ALL cells both *in vitro* and *in vivo*. Cyclin-dependent kinase 6 (CDK6) inhibition by sodium butyrate or PD-0332991 decreased ALL cell growth *in vitro*, whereas overexpression of pre-miR124a led to decreased tumorigenicity in a xenogeneic *in vivo* Rag2<sup>-/-</sup>γc<sup>-/-</sup> mouse model. The clinical implications of these findings were analyzed in a group of 353 patients diagnosed with ALL. Methylation of *hsa-miR-124a* was observed in 59% of the patients, which correlated with down-regulation of *miR-124a* ( $P < 0.001$ ). Furthermore, hypermethylation of *hsa-miR-124a* was associated with higher relapse rate ( $P = 0.001$ ) and mortality rate ( $P < 0.001$ ), being an independent prognostic factor for disease-free survival ( $P < 0.001$ ) and overall survival ( $P = 0.005$ ) in the multivariate analysis. These results provide the grounds for new therapeutic strategies in ALL either targeting the epigenetic regulation of microRNAs and/or directly targeting the CDK6-Rb pathway. [Cancer Res 2009;69(10):4443–53]

## Introduction

MicroRNAs (miRNA) are small, non-protein-coding RNAs of 19 to 25 nucleotides that regulate gene expression by targeting mRNAs in a sequence-specific manner, inducing translational repression or mRNA degradation (1, 2) and playing important roles in cell processes such as proliferation, apoptosis, differentiation, or even in tumorigenesis (reviewed in ref. 3). A systematic search for a correlation between the genomic position of miRNAs and the location of cancer-associated regions revealed that more than half of the mapped miRNAs are located at fragile chromosome regions involved in human cancer (4). MiRNA expression profiles also indicate that most miRNAs have lower expression levels in tumors compared with normal tissues (5), suggesting that some of these miRNAs may act as putative tumor suppressor genes (6). Whereas hundreds of miRNAs are discovered and various functions of miRNAs have been intensively studied, the mechanisms that control their expression are largely unknown.

In cancer, transcriptional silencing due to epigenetic mechanisms is one of the most important alterations (7). DNA hypermethylation of tumor suppressor genes, global genomic hypomethylation, and aberrant histone modification signatures are the three most important epigenetic alterations associated with malignant transformation (8). The fact that miRNA expression occurs in a tissue-specific or developmental stage-specific manner and that some miRNAs are imprinted (9), supports the hypothesis that DNA methylation may regulate miRNA expression as recent studies have indicated (10–14). Therefore, it is conceivable that DNA methylation regulates miRNA expression during tumorigenesis (15).

We and others have extensively shown that hypermethylation of gene promoters is a frequent mechanism of gene silencing and a finding associated with the prognosis of the disease and response to therapy in patients with acute lymphoblastic leukemia (ALL; refs. 16–21). Methylation in human ALL cells participates in the inactivation of key cellular pathways such as cell cycle (21), apoptosis (22), and cell-cell adhesion (23). Moreover, aberrant methylation of CpG islands is quantitatively different in individual tumors within the same tumor type, and this patient-specific methylation profile provides important prognostic information in ALL patients (17–19). The presence in individual tumors of multiple epigenetic events that affect different pathways implicated in cell survival and proliferation, such as the WNT pathway, also provides important insights into the pathogenesis of ALL (16).


**Note:** Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

X. Agirre and A. Vilas-Zornoza contributed equally to this work.

**Requests for reprints:** Felipe Prósper, Hematology and Cell Therapy, Clínica Universitaria, Avenida Pío XII 36, Pamplona 31008, Spain. Phone: 34-948-255400; Fax: 34-948-296500; E-mail: fprosper@unav.es or José Román-Gómez, Hematology Department, Reina Sofia Hospital, Avenida Menendez Pidal s/n, 14004 Cordoba, Spain. Phone: 34-957-010250; Fax: 34-957-010429; E-mail: peperosa@teleline.es.

©2009 American Association for Cancer Research.

doi:10.1158/0008-5472.CAN-08-4025



**Figure 1.** Expression of *hsa-miR-124a* is regulated epigenetically in ALL-derived cell lines. **A**, quantitative ChIP-PCR analysis for the histone marks 3mK4H3, ACh3, 2mK9H3, 3mK9H3, and 3mK27H3 in the *hsa-miR-124a-1*, *124a-2*, and *124a-3* CpG islands. Values are expressed as the percentage of the corresponding histone mark in ALL-derived TOM-1 and NALM-20 cell lines in comparison with expression in bone marrow human lymphocytes (HL; 100%). **B**, bisulfite sequencing and MSP analysis of the *hsa-miR-124a-1*, *124a-2*, and *124a-3* CpG island regions in positive methylated control (MC), HL, and ALL-derived cell lines. Each box indicates a CpG dinucleotide (white box, unmethylated; black box, methylated). U, unmethylated allele; M, methylated allele. **C**, quantitative ChIP-PCR analysis of the histone mark ACh3 in the *hsa-miR-124a-1*, *124a-2*, and *124a-3* CpG island regions in TOM-1 and NALM-20 cell lines before and after treatment with trichostatin A. **D**, quantitative real-time MSP analysis of the *hsa-miR-124a-1*, *124a-2*, and *124a-3* CpG island regions in TOM-1 and NALM-20 cell lines before and after treatment with 5-aza-2'-dCyd or trichostatin A. TRI, trichostatin A; AZA, 5-aza-2'-dCyd. **A**, **C**, and **D**, columns, mean of three independent experiments; bars, SD. **B**, representative experiment of at least three different studies.

All these data suggest the putative presence of DNA methylation-associated silencing of miRNAs in ALL cells. To explore this hypothesis, we analyzed the epigenetic regulation of miRNAs in ALL by chromatin immunoprecipitation (ChIP)-on-Chip using

histone marks of closed and open chromatin, identifying the *miR-124a* loci as a potential candidate for epigenetic silencing. Methylation and expression analysis showed that DNA methylation contributes to the transcriptional down-regulation of *miR-124a* in

ALL, and that this epigenetic event affects the proliferative potential of the leukemic cells by modulating cyclin-dependent kinase 6 (CDK6). Abnormal methylation of *miR-124a* in ALL showed a negative prognostic effect in ALL patients. These results provide a rationale for the use of epigenetic drugs and CDK6 inhibitors in the treatment of ALL.

## Materials and Methods

**Cell lines and patients.** Six ALL-derived cell lines (TOM-1, NALM-20, MY, LOUCY, JOURKAT, and TANOUE) were purchased from the DSMZ (Deutsche Sammlung von Microorganismen und Zellkulturen GmbH) and grown as described (16). We studied 353 patients (210 male and 143 female) with *de novo* ALL who were enrolled in successive multicenter studies of the *Programa para el estudio y tratamiento de las hemopatias malignas* (PETHEMA) Spanish study group. Clinical characteristics of the patients are listed in Supplementary Table S1 and Supplementary Materials and Methods.

**Chromatin immunoprecipitation.** Lymphocytes from peripheral blood of healthy donors, TOM-1 and NALM-20 cell lines, were subjected to ChIP. The ChIP assays were done as previously described (ref. 11; Supplementary Materials and Methods).

**DNA methylation analyses.** Methylation status was analyzed by methylation-specific PCR (MSP) using primers specific for either the methylated or bisulfite modified unmethylated DNA (Supplementary Table S2 and Supplementary Materials and Methods).

**Treatment of all cell lines.** ALL-derived TOM-1 and NALM-20 were treated with 4  $\mu\text{mol/L}$  of 5-aza-2'-deoxycytidine (5-aza-2'-dCyd; Sigma-Aldrich) for 4 d, 50 nmol/L of trichostatin A for 4 d, 1 and 10 mmol/L of sodium butyrate for 2 to 4 d, and 1  $\mu\text{mol/L}$  of PD-0332991 (Pfizer) for 24 h (Supplementary Materials and Methods).

**Quantitative expression analysis of *hsa-miR-124a* and *CDK6* genes.** Expression of the different miRNAs and genes was analyzed with specific primers and TaqMan probe according to the TaqMan MicroRNA Assay protocol (Applied Biosystems; Supplementary Table S2 and Supplementary Materials and Methods).

**RNA and miRNA transfection.** The pre-miR-124a precursor molecule, negative precursor-miR control, siCDK6-select (43900824 ID: S53), and negative siRNA#1 control were purchased from Ambion and used for transfection studies (Supplementary Materials and Methods).

**Western blot analysis.** Proteins extracted from the ALL-derived cell lines TOM-1 and NALM-20 were analyzed by Western blot as previously described (ref. 16; Supplementary Materials and Methods).

**In vivo transplantation studies.** Animal studies were done according to institutional guidelines. The ALL-derived cell line TOM-1 was transfected *in vitro* with pre-miR-124a precursor molecule or precursor-miR control. Untransfected cells (mock) or cells transfected with the empty plasmid were used as controls. Twenty-four hours after transfection,  $5 \times 10^6$  viable cells were injected s.c. into the left flanks of 6-wk-old female BALB/cA-Rag2<sup>-/-</sup> $\gamma\text{c}^{-/-}$  mice ( $n = 6$  per group). Mice were sacrificed after 20 d, and sizes of tumors were measured. Tumor volumes were calculated by using the equation  $V (\text{mm}^3) = (A \times B^2)/2$ , where  $A$  is the largest diameter and  $B$  is the perpendicular diameter. The tumor volume of mice injected with TOM-1 cells transfected with the precursor-miR control was considered as reference.

**Statistical analysis.** For statistical purposes, residual values of tumor volume were used to test for normal distribution using Shapiro-Wilk's test. One-way ANOVA and Tamhane T2 multiple comparison test, after Levene's analysis, were used to compare the mouse groups.  $P < 0.05$  was considered significant in all statistical tests (detailed statistical analysis is provided in Supplementary Materials and Methods).


## Results

**Expression of *hsa-miR-124a* in ALL cells is regulated by histone modification and CpG island hypermethylation.** Our ChIP-on-Chip analysis of 27,800 CpG islands using two ALL cell

lines (TOM-1 and NALM-20) revealed that 11 of the 78 CpG islands that embedded or were close to known 13 miRNAs genes presented a decrease of 3mK4H3 and/or an increase of 2mK9H3 marks in ALL-derived cell lines in comparison with healthy donor samples (a pattern of histone modifications underlying a closed chromatin structure associated with repressive gene expression; Supplementary Table S3). Among the 13 miRNAs presumably regulated by histone modifications, we decided to focus on *hsa-miR-124a* miRNA family. Although *hsa-miR-124a* corresponds to a single mature miRNA, there are three genomic loci [*hsa-miR-124a-1* (8p23.1), *hsa-miR-124a-2* (8q12.3), and *hsa-miR-124a-3* (20q13.33)] that encode for the same mature miRNA. Interestingly, the *hsa-miR-124a-1* and *hsa-miR-124a-3* genes are located within CpG islands whereas *hsa-miR-124a-2* is 760 bp downstream of a CpG island. Recent studies have shown in colon cancer that the corresponding CpG islands of all three genes are methylated (11) whereas *hsa-miR-124a-1* and *hsa-miR-124a-3* are frequently methylated in acute myeloid leukemia (AML; ref. 24). The results obtained by the ChIP-on-Chip analysis were verified using quantitative PCR assay showing a decrease of 3mK4H3 and/or an increase of 2mK9H3 marks in ALL-derived TOM-1 and NALM-20 cell lines in comparison with healthy donor samples for all three miRNAs [*hsa-miR-124a1* (8p23.1), *hsa-miR-124a2* (8q12.3), and *hsa-miR-124a3* (20q13.33); Fig. 1A]. In addition, we analyzed the levels of Ach3, 3mK9H3, and 3mK27H3 in the same samples by quantitative PCR and observed a decrease of Ach3 and an increase of 3mK9H3 and 3mK27H3, all of these marks being associated with a closed chromatin structure (Fig. 1A).

Next, we analyzed the methylation of the CpG island-associated *hsa-miR-124a* (*hsa-miR-124a1*, *hsa-miR-124a2*, and *hsa-miR-124a3*) in ALL-derived cell lines by bisulfite genomic sequencing and MSP (Fig. 1B). *Hsa-miR124a1* and *hsa-miR-124a3* were hypermethylated in every cell line (with the exception of MOLT-4 in which *hsa-miR124a1* was not methylated) but not in healthy lymphocytes. However, nonneoplastic marrow lymphocytes or peripheral blood lymphocytes displayed *hsa-miR-124a2* methylation (Fig. 1B). Therefore, a quantitative real-time MSP was done to quantify *hsa-miR-124a2* methylation. Based on the background fluorescence intensity, a cutoff level was determined for specific fluorescence for both methylated *hsa-miR-124a2* sequences and *Alu* control sequences in normal lymphocytes. This threshold was used to calculate the cycle threshold or crossing point ( $C_p$ ) of each sample. The  $C_p$  value was directly proportional to the amount of target sequence present in the sample. The normal sample that showed the lowest difference in  $C_p$  between the target (methylated sequences) and the reference (*Alu* sequence) genes was used as a control sample for relative quantification of the *hsa-miR-124a2* CpG island methylation in both healthy individuals and ALL samples and was considered as 100% normalized ratio. Based on these prerequisites and to determine the cutoff value for altered *hsa-miR-124a2* methylation in ALL samples, we quantified by quantitative real-time MSP the methylation status of the *hsa-miR-124a2* CpG island in 30 healthy donors.  $N_{\text{hsa-miR124a2}}$  ratios fell between 65% and 100% ( $85 \pm 15\%$ ). A  $N_{\text{hsa-miR124a2}}$  ratio  $\geq 130\%$  (determined as the mean + 3 SD) was chosen to define hypermethylation of *hsa-miR-124a2* in ALL DNA samples. By quantitative real-time MSP, the CpG island of *hsa-miR-124a2* was revealed to be hypermethylated in all ALL-derived cell lines studied (median  $N_{\text{hsa-miR124a2}}$ ,  $180 \pm 38\%$ ).

Whereas expression of *hsa-miR-124a* was significantly down-regulated in ALL cell lines in comparison with peripheral blood



**Figure 2.** *Hsa-miR-124a* transfection decreases ALL cell growth *in vitro* and *in vivo*. **A**, expression analysis of *hsa-miR-124a* measured by quantitative reverse transcription-PCR (RT-PCR). Expression of *hsa-miR-124a* in TOM-1 and NALM-20 cells transfected with scrambled control was considered as 100% expression. **B**, cell viability and total cell counts of transfected TOM-1 cells were determined at various times by trypan blue exclusion. TOM-1 cells transfected with scrambled pre-miR were used as control. **C**, apoptosis was measured by Cell Death Detection ELISA kit. **A** to **C**, columns, mean from three independent experiments; bars, SD. **D**, comparison of tumor size in female BALB/cA-Rag2<sup>-/-</sup>γc<sup>-/-</sup> mice transplanted with TOM-1 transfected with pre-miR-124a, TOM-1 transfected with scrambled, or TOM-1 cells 20 d after s.c. injection of cells. Columns, mean tumor volume in BALB/cA-Rag2<sup>-/-</sup>γc<sup>-/-</sup> mice (six different animals per condition and a representative example); bars, SD. \*,  $P < 0.01$ ; \*\*,  $P < 0.001$ .

lymphocytes from healthy donors (Supplementary Fig. S1), treatment of ALL cell lines with trichostatin A (HDAC inhibitor) or with the demethylating agent 5-aza-2'-dCyd induced an up-regulation of *hsa-miR-124a* expression (Fig. 1C), indicating that, indeed, expression of *hsa-miR-124a* is regulated epigenetically. Treatment with trichostatin A induced an increase of ACh3 levels in the three miRNA genomic regions, whereas demethylation of the three CpG island-associated *hsa-miR-124a* was observed after treatment with 5-aza-2'-dCyd in TOM-1 and NALM-20 cell lines (Fig. 1D). All these results indicate that methylation and chromatin modification are responsible, at least in part, for the abnormal down-regulation of *hsa-miR-124a* expression in ALL cells.


#### Up-regulation of *hsa-miR-124a* decreases ALL cell growth.

To determine the role of *hsa-miR-124a* in ALL, expression of *hsa-miR-124a* was up-regulated in ALL-derived TOM-1 cells by nucleofection with pre-miR-124a, and cell growth was evaluated and compared with cells transfected with pre-miR scrambled control and nontransfected cells. An increase in *hsa-miR-124a* expression (Fig. 2A) induced a decrease in cell growth (Fig. 2B) in comparison with cells transfected with pre-miR scrambled or nontransfected cells. Decreased cell growth was not associated with increased apoptosis as indicated by the lack of changes observed after treatment with pre-miRNA, scrambled control, or nontransfected cells (Fig. 2C). Expression of *hsa-miR-124a* *in vitro*


decreased progressively throughout the culture. The level of expression remained above the control at day 8 to 10 and returned to control levels (no expression) by day 15 to 20 after transfection (Supplementary Fig. S2A). These results suggest that down-regulation of *hsa-miR-124a* could be associated with an increase in cell proliferation at least *in vitro*.

To further study the putative tumor-suppressive function of *hsa-miR-124a* *in vivo*,  $5 \times 10^6$  viable TOM-1 untransfected cells, transfected *in vitro* with pre-miR scrambled control or pre-miR-124a precursor molecule, were injected s.c. into the left flanks of 6-week-old female BALB/cA-Rag2<sup>-/-</sup> $\gamma$ c<sup>-/-</sup> mice. Whereas animals transplanted with untransfected cells or with scrambled pre-miR control developed large tumors after 20 days, animals

receiving TOM-1 cells transfected with pre-miR-124a showed a very significant decrease in tumor growth (Fig. 2D). At day 20, the median tumor volumes in the untransfected and empty vector-treated mice were 3,939.05 mm<sup>3</sup> (881.29) and 4,426.5 mm<sup>3</sup> (1,936.32;  $P = 0.932$ ), respectively, whereas in mice inoculated with TOM-1 cells transfected with pre-miR-124a, the volume was 1,182.03 mm<sup>3</sup> (968.4), significantly lower than that in mice transplanted with cells treated with empty vector ( $P = 0.022$ ; Fig. 2D). Histologic analysis of the tumors showed tumors infiltrated by lymphoblast, characteristic of ALL (Supplementary Fig. S3). These results together with the *in vitro* experiments indicate that down-regulation of *hsa-miR-124a* mediates cell growth in ALL and supports the role of *hsa-miR-124a* as a tumor suppressor gene.



**Figure 3.** *Hsa-miR-124a* expression mediates activation of *CDK6-Rb* in ALL cells. *A*, complementarity between *hsa-miR-124a* and *CDK6* 3'-UTR as predicted by PICTAR (<http://pictar.bio.nyu.edu/>). Green, *hsa-miR-124a* sequence; red, *CDK6* 3'-UTR sequence. *B*, *CDK6* mRNA expression analysis by quantitative RT-PCR and protein level analysis of *CDK6*, *Rb-P*, and *Rb-Total* by Western blot in ALL-derived TOM-1 and NALM-20 cell lines transfected with pre-miR-124a molecule and scrambled precursor control. Expression of *CDK6* in TOM-1 and NALM-20 cells transfected with scrambled pre-miR control was considered as 100% expression. Tubulin was used as a loading control in Western blot analysis. *C*, *CDK6* mRNA expression analysis by quantitative RT-PCR in ALL-derived TOM-1 and NALM-20 transfected with negative siRNA#1 control and siCDK6. TOM scrambled and NALM scrambled (cells transfected with negative siRNA#1 control) were considered as 100% expression.  $\beta$ -Actin was used as a loading control in Western blot analysis. *D*, Western blot analysis of *CDK6*, *Rb-P*, and *Rb-Total* levels in ALL-derived TOM-1 and NALM-20 transfected with negative siRNA#1 control and siCDK6. Tubulin was used as a loading control. *B* and *C*, columns, mean of three experiments; bars, SD. *B* and *D*, representative study of three different experiments.



**Figure 4.** Inhibition of the CDK6-Rb pathway by sodium butyrate and PD-0332991 leads to decreased growth and induction of apoptosis of ALL cells. TOM-1 and NALM-20 cells were treated with 1 and 10 mmol/L of sodium butyrate for 48 and 72 h (A and B) or 1  $\mu$ mol/L PD-0332991 (C and D). A, *CDK6* mRNA analysis by quantitative RT-PCR, protein level analysis by Western blot, and cell viability (determined at various times by trypan blue exclusion) in TOM-1 and NALM-20 cell lines treated with sodium butyrate. B, apoptosis of TOM-1 and NALM-20 cell lines treated with sodium butyrate measured by Cell Death Detection ELISA kit and Western blot of the 85-kDa fragment of poly(ADP-ribose) polymerase (PARP). C, Western blot analysis of CDK6, Rb-P, and Rb-Total levels in ALL-derived TOM-1 and NALM-20 treated with PD-0332991, and cell apoptosis measured by Cell Death Detection ELISA kit.  $\beta$ -Actin was used as a loading control. D, cell viability in TOM-1 and NALM-20 cell lines treated with PD-0332991 (determined at various times by trypan blue exclusion) and cell cycle analysis (propidium iodide only in NALM-20). Blue, control cells; green, cells treated with PD-0332991. A representative study of three different experiments or mean ( $\pm$ SD) of three independent experiments is shown. E.F., enrichment factor.


***Hsa-miR-124a* regulation of ALL cell growth is mediated through CDK6-Rb.** It has been previously shown that *CDK6* is a direct target of *hsa-miR-124a* (11), and as predicted by PICTAR,<sup>7</sup>

there is a complementarity between *hsa-miR-124a* and *CDK6* 3' untranslated region (UTR; Fig. 3A). Thus, to determine the potential role of *hsa-miR-124a* in the regulation of ALL cell growth in ALL cells and to experimentally validate if *CDK6* is a target for *hsa-miR-124a* in ALL, we analyzed *CDK6* mRNA and protein levels in human ALL-derived cell lines after reexpression of


<sup>7</sup> <http://pictar.bio.nyu.edu>

*hsa-miR-124a*. ALL-derived TOM-1 and NALM-20 cells nucleofected with pre-miR-124a showed an increase in expression of *hsa-miR-124a* (Fig. 2A) and a decrease in *CDK6* mRNA and CDK6 and phosphorylated retinoblastoma (Rb-P) protein (Fig. 3B) levels in comparison with cells transfected with pre-miR scrambled control or empty vector. Inhibition of CDK6 expression *in vitro* was transitory and correlated inversely with expression of *hsa-miR-124a*, so that 8 days after transfection, it remained down-regulated but its expression was restored to normal levels by day 15 after transfection (Supplementary Fig. S2B). These results indicate that the epigenetic silencing of *hsa-miR-124a* in ALL leads to the activation of the CDK6-Rb oncogenic pathway. Interestingly, down-regulation of *CDK6* expression induced by transfection of TOM-1 and NALM-20 cell lines with siRNA against *CDK6* (Fig. 3C) was associated with a decrease in Rb phosphorylation (Fig. 3D), which further suggested the potential role of the CDK6-Rb pathway in ALL.

**Inhibition of the CDK6-Rb pathway leads to decreased ALL cell proliferation and growth.** The fact that CDK6 is involved in cell cycle progression and differentiation (11) and the existence of several molecules that inhibit CDK6 activity such as sodium butyrate (25) or PD-0332991 (26) establish *CDK6* as an attractive target in ALL. To show the role of *CDK6* in the pathogenesis of ALL, TOM-1 and NALM-20 cell lines were treated with sodium butyrate and PD-0332991. Incubation of ALL cells with 1 and 10 mmol/L of sodium butyrate for 48 and 72 hours induced down-regulation of *CDK6* mRNA and protein expression levels, decreased cell growth (Fig. 4A), and increased apoptosis (Fig. 4B), in contrast to up-regulation of *hsa-miR-124a*, which did not induce apoptosis. This effect probably is due to the fact that sodium butyrate is not a specific inhibitor of *CDK6* but can also inhibit other pathways involved in cell cycle and apoptosis, such as p53, cyclin D1, or histone deacetylase (27, 28).



**Figure 5.** Methylation analysis of *hsa-miR-124a* in patients with ALL. **A**, methylation frequencies for *hsa-miR-124a1*, *124a2*, and *124a3* in ALL patient samples and methylation frequencies for *hsa-miR-124a*. **B**, expression of *hsa-miR-124a* and *CDK6* measured by quantitative RT-PCR in the nonmethylated and methylated groups of patients with ALL (\*\*,  $P < 0.001$ ). **C**, MSP analysis of *hsa-miR-124a-1* and *124a-3* and expression of *hsa-miR-124a* measured by quantitative RT-PCR.



**Figure 6.** Kaplan-Meier survivor function for ALL patients. *A*, DFS curves for all the patients enrolled in this study, childhood ALL and adult ALL according to the methylation profile. *B*, OS curves for all the patients enrolled in this study, childhood ALL and adult ALL according to the methylation profile. *Solid lines*, nonmethylated patients; *dashed lines*, methylated patients.

Next, we examined the effect in ALL cell lines of the small molecule PD-0332991 (26), a recently described specific inhibitor of *CDK4/6*. Treatment of TOM-1 and NALM-20 cells with 1  $\mu\text{mol/L}$  PD-0332991 for 24 hours induced dephosphorylation of the Rb protein without changes in the protein levels of CDK6 or Rb, consistent with the mechanism of PD-0332991-mediated inhibition of CDK activity but with lack of transcription/translation inhibition (Fig. 4C). Treatment of ALL cell lines with 1  $\mu\text{mol/L}$  PD-0332991 for 5 days induced a significant inhibition of cell growth and proliferation (Fig. 4D), but unlike sodium butyrate, it had no effect on cell apoptosis as shown by the analysis of oligonucleosomal fragments (Fig. 4A). This is in agreement with previous studies on multiple myeloma in which a combination of PD-0332991 with dexamethasone was required to induce cell apoptosis of myeloma cells, whereas treatment with PD-0332991 alone was able to induce inhibition of cell proliferation (29).

**Expression of *hsa-miR-124a* in patients with ALL is regulated by CpG island hypermethylation.** To determine the role of epigenetic regulation of *hsa-miR-124a* in a more clinically relevant model, we analyzed the methylation status of the three CpG islands associated with *hsa-miR-124a* in a group of 353 ALL patients (Supplementary Table S1). Methylation frequencies were as follows: 49% for *hsa-miR-124a1*, 46% for *hsa-miR-124a2*, and 42% for *hsa-miR-124a3* (Fig. 5A). No methylated miRNAs were found in

145 of 353 patients (nonmethylated group, 41%) whereas most ALLs [208 of 353 (59%)] had methylation of at least one miRNA (methylated group, Fig. 5A). Methylation of the three *hsa-miR-124a* genes was significantly associated (Supplementary Table S4). Expression of *hsa-miR-124a* was also down-regulated in patients with methylation of *hsa-miR-124a* in comparison with nonmethylated patients ( $32 \pm 36\%$  versus  $96 \pm 43\%$ ;  $P < 0.001$ ; Fig. 5B) with a correlation between methylation and expression (Fig. 5C), indicating that expression of *hsa-miR-124a* was regulated, at least in part, by methylation. In line with the studies in cell lines, patients with methylation of *hsa-miR-124a* showed a significant up-regulation of *CDK6* expression compared with nonmethylated patients ( $332 \pm 217\%$  versus  $167 \pm 115\%$ ;  $P < 0.001$ ; Fig. 5B).

**Clinical outcome and *hsa-miR-124a* methylation profile.** Finally, to determine whether methylation and expression of *hsa-miR-124a* was associated with prognosis in patients with ALL, we analyzed the outcome of a series of 353 patients diagnosed and treated uniformly within the PETHEMA study group. As shown in Supplementary Table S1, clinical and laboratory characteristics did not differ significantly between patients with methylated or unmethylated *hsa-miR-124a*, with the exception of higher WBC counts and the presence of more frequent *BCR-ABL* positivity among methylated patients. Other poor-risk cytogenetics or molecular events, risk groups according to both National Cancer

Institute and PETHEMA classifications, good risk features (hyperdiploidy and *TEL-AML1* fusion), type of PETHEMA protocol administered, and number of patients who received stem cell transplantation were similarly distributed between the two methylation groups. A separate analysis of adult and childhood ALL patients gave the same results as the global series.

Supplementary Table S1 details the relapse history, complete remission (CR) rates, and mortality for patients included in the different methylation groups. CR rates of patients in the non-methylated and methylated groups were 93% and 88%, respectively, accounting for a 91% overall CR rate. This suggests that methylation profile did not correlate with response to remission induction therapy. However, patients in the nonmethylated group had a lower relapse rate compared with patients in the methylated group (26% versus 57%;  $P < 0.001$ ). Mortality rate was also lower for the nonmethylated group compared with the methylated group (34% versus 56%;  $P < 0.001$ ). Similar results were obtained in separate analyses of children [relapse rate, 17% for nonmethylated group versus 44% for methylated group ( $P = 0.001$ ); mortality rate, 21% for nonmethylated group versus 31% for methylated group ( $P = 0.09$ )] and adults [relapse rate, 38% for nonmethylated group versus 69% for methylated group ( $P = 0.002$ ); mortality rate, 50% for nonmethylated group versus 80% for methylated group ( $P < 0.001$ )].

Disease-free survival (DFS) among patients who achieved CR according to the methylation profile showed that the estimated DFS rates at 14 years were 68% and 29% for the nonmethylated [mean survival time, 147.81 months; 95% confidence interval (95% CI), 130.18–165.43] and methylated (mean survival time, 59.78 months; 95% CI, 47.62–71.94) groups, respectively ( $P < 0.0001$ ; Fig. 6A). Among children, the 14-year DFS was 75% for non-methylated group (mean survival time, 143.87 months; 95% CI, 127.38–160.36) and 43% for methylated group (mean survival time, 82.55 months; 95% CI, 64.9–100.20;  $P = 0.0001$ ; Fig. 6A). Among adult ALL patients, the 13-year DFS was 56% for nonmethylated group (mean survival time, 121.25 months; 95% CI, 91.37–151.14) and 10% for methylated group (mean survival time, 32.69 months; 95% CI, 20.61–44.77;  $P = 0.0002$ ; Fig. 6A). The actuarial overall survival (OS) at 14 years calculated for all leukemic patients was 61% for nonmethylated patients (mean survival time, 134.69 months; 95% CI, 117.49–151.89) and 32% for methylated patients (mean survival time, 64.41 months; 95% CI, 53.31–75.51;  $P < 0.0001$ ; Fig. 6B). Differences were observed in the actuarial OS among the nonmethylated and methylated groups in separate analyses of children [73% (mean survival time, 144.64 months; 95% CI, 127.34–161.94) and 62% (mean survival time, 105.58 months; 95% CI, 89.60–121.56), respectively;  $P = 0.09$ ; Fig. 6B] and adults [45% (mean survival time, 101.38 months; 95% CI, 74.29–128.46) and 9% (mean survival time, 31.30 months; 95% CI, 21.56–41.05), respectively;  $P = 0.0002$ ; Fig. 6B]. Finally, a multivariate analysis of potential prognostic factors (including the type of PETHEMA protocol applied) showed that hypermethylation profile was an independent prognostic factor in predicting DFS in the global series ( $P < 0.001$ ) as well as in both childhood ( $P = 0.007$ ) and adult ALLs ( $P = 0.01$ ; Supplementary Table S5). Methylation status was also independently associated with OS in the global series ( $P = 0.005$ ) and adult ALL ( $P = 0.01$ ; Supplementary Table S6).

## Discussion

Epigenetic dysregulation of miRNAs in human cancer (30) constitutes an emerging mechanism implicated in the development

of cancer that may have significant consequences for cancer patients undergoing treatment with DNA-demethylating agents (31). Although our approach using ChIP-on-Chip yielded a number of miRNAs regulated by histone modifications (32), we decided to focus on *hsa-miR-124a* as a potential tumor suppressor gene with a role in the pathogenesis of ALL for several reasons: (a) The epigenetic regulation of *hsa-miR-124a* had been recently described in colon cancer and medulloblastoma. (b) Hypermethylation of gene promoters is a frequent mechanism of gene silencing and a finding associated with prognosis and response to therapy in ALL (19–22). (c) There was a known target gene of *hsa-miR-124a*, such as *CDK6*, a classic oncogene involved in cell proliferation and differentiation (33, 34). (d) *CDK6* constitutes an attractive candidate for the use of small inhibitory molecules (26). The results of the study clearly support the approach, showing that epigenetic manipulation of *hsa-miR-124a* or pharmacologic inhibition of *CDK6* results in inhibition of leukemic cell growth both *in vitro* and *in vivo*, and that methylation and down-regulation of *hsa-miR-124a* represents an independent prognostic factor in patients with ALL.

MiRNAs have been implicated in the pathogenesis of malignant and nonmalignant disease (35); however, information about the role of miRNA expression as prognostic factor in different tumors has only been recently described (36, 37). Using a miRNA summary value obtained from the analysis of 64 patients with cytogenetically normal AML and validated in another 55 patients, Marcucci and colleagues (36) recently showed the association between miRNA signature and clinical outcome, and more specifically, it was shown that the expression of miRNA-181 family members was associated with event-free survival. Using a similar approach in 84 patients with colon cancer, it was shown that high expression of *miR-21* is associated with poor survival and patient outcome (37). In our study, using a large sample of patients with ALL ( $n = 353$ ), we show that epigenetic regulation and expression of a specific miRNA defines a group of patients with ALL associated with poor outcome independently of other risk factors. Although the prognostic value of hypermethylation of cancer-related genes in patients with ALL has already been shown (16, 17), this is the first study to show that hypermethylation of a miRNA is independently associated with prognosis in ALL. The fact that methylation of *hsa-miR-124a* was also associated with other established risk factors such as WBC count or Ph positivity does not limit our conclusion because epigenetic regulation of *hsa-miR-124a* remains an independent prognostic factor in the multivariate analysis. This association should help in tailoring the treatment of patients with ALL.

An interesting and clinically relevant conclusion of our study is the role for *CDK6* in the abnormal behavior of ALL cells. *CDK6* is a member of a family of serine-threonine kinases involved in the control of cell cycle progression (38). *CDK6* partners with cyclin D to phosphorylate the Rb protein during the G<sub>1</sub>-S cell cycle transition. Although CDKs are not essential for cell cycle progression (39), it has been well established that inappropriate regulation of CDKs is one of the most frequent alterations in human cancer, making CDKs an attractive target for the development of new inhibitors (40). Most of the information about the role of cyclin-dependent proteins in ALL is related to cyclins and cyclin-dependent kinase inhibitors such as p27<sup>kip</sup> or p21 (41, 42). However, our *in vitro* results using ALL cell lines and a *CDK6* inhibitor (PD-0332991) indicate that inhibition of this pathway maybe an effective therapy for ALL patients. A caveat to this conclusion is that a combination of PD-0332991 with other drugs

capable to induce apoptosis may be required, as suggested by the fact that PD-0332991 was able to induce cell cycle inhibition but not cell apoptosis. Similar findings have been reported in a recent study using myeloma cells and a CDK4/6 inhibitor (43). PD-0332991 potently inhibited CDK4/6-specific phosphorylation of Rb and cell cycle progression in myeloma cells, leading to induction of cell cycle arrest and increasing the sensitivity of myeloma cells to killing by bortezomib, but not inducing cell apoptosis on its own (43). Similar conclusions can be drawn from the *in vivo* studies with Rag2<sup>-/-</sup>γc<sup>-/-</sup>: Although expression of pre-miR-124a induced a decrease in cell growth, ALL cells eventually were able to continue proliferating once the expression of pre-miR-124a was down-regulated and *CDK6* expression was again up-regulated (as suggested by *in vitro* time course analysis of *hsa-miR-124a* and *CDK6* expression; Supplementary Fig. S2). The capacity of the cells to eventually override the growth inhibition induced by *hsa-miR-124a* could also be related to the existence of other epigenetically regulated miRNAs that would affect the expression of *CDK6*. In fact, miRNA-34b/c has been described to regulate the expression of *CDK6* and also to be epigenetically silenced in colorectal carcinoma (13), and we have preliminary evidence that miRNA-34b/c is hypermethylated in ALL.<sup>8</sup> Taking all these considerations together, we believe inhibition of CDK6 to be more specific and clinically relevant for patients with ALL, inducing the overexpression of *hsa-miR-124a*.

In addition to the marks used in the ChIP-on-Chip analysis, we examined other histone marks associated with chromatin state such as the repressive mark 3mK27H3 associated with the polycomb repressive complex 2 (PRC2; ref. 44). Recent studies in both malignant and normal stem cells have hypothesized that

genes involved in pluripotency and malignant transformation are present in a "bivalent" chromatin state expressing both marks of open (3mK4H3) and closed (3mK27H3) chromatin, and that genes repressed by PRC2 proteins may be susceptible to hypermethylation, leading to tumor progression (45). Interestingly, the results of our work indicate that *hsa-miR-124a* as well as some of the other miRNAs identified in the ChIP-on-Chip analysis is regulated by PRC2 and by hypermethylation of their promoters. In that sense, it would be interesting to determine the chromatin state of these genes not only in the leukemic population but also in the population of leukemia-initiating cells to provide new evidence supporting the epigenetic progenitor origin of cancer hypothesis (46).

In summary, we show that the epigenetic regulation of *hsa-miR-124a* mediates, at least in part, the increased expression of *CDK6* and contributes to the abnormal proliferation of ALL cells both *in vitro* and *in vivo*. Furthermore, hypermethylation of *hsa-miR-124a* is an independent prognostic factor for DFS and OS in patients with ALL. All these findings open the possibility of new therapeutic strategies for patients with ALL, either targeting epigenetically regulated genes using drugs that inhibit methylation and histone modifications and/or directly targeting the CDK6 protein.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Acknowledgments

Received 10/18/08; revised 2/12/09; accepted 3/5/09.

**Grant support:** Beca Ortiz de Landazuri 2006, Departamento de Salud-Gobierno de Navarra; Fondo de Investigación Sanitaria (Spain) grants PI070602, PI070608, PI060003, CP07/00215, and RD06/0020; Junta de Andalucía grants 0386/2006 and 0004/2007; Kinder-Krebs Initiative Buchholz, Holm-Seppensen (KKI); and funds from AMI and "UTE project CIMA."

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>8</sup> Unpublished observations.

## References

- He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet* 2004;5:522–31.
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004;116:281–97.
- Chen CZ. MicroRNAs as oncogenes and tumor suppressors. *N Engl J Med* 2005;353:1768–71.
- Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc Natl Acad Sci U S A* 2004;101:2999–3004.
- Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. *Nature* 2005;435:834–8.
- Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A* 2002;99:15524–9.
- Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? *Nat Rev Cancer* 2006;6:107–16.
- Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. *N Engl J Med* 2003;349:2042–54.
- Seitz H, Youngson N, Lin SP, et al. Imprinted microRNA genes transcribed antisense to a reciprocally imprinted retrotransposon-like gene. *Nat Genet* 2003;34:261–2.
- Bueno MJ, Perez de Castro I, Gomez de Cedron M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. *Cancer Cell* 2008;13:496–506.
- Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. *Cancer Res* 2007;67:1424–9.
- Datta J, Kutay H, Nasser MW, et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. *Cancer Res* 2008;68:5049–58.
- Toyota M, Suzuki H, Sasaki Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. *Cancer Res* 2008;68:4123–32.
- Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. *Cancer Res* 2008;68:2094–105.
- Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. *Cancer Cell* 2006;9:435–43.
- Roman-Gomez J, Cordeu L, Agirre X, et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. *Blood* 2007;109:3462–9.
- Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. *Blood* 2004;104:2492–8.
- Roman-Gomez J, Jimenez-Velasco A, Agirre X, Prosper F, Heiniger A, Torres A. Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. *J Clin Oncol* 2005;23:7043–9.
- Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. *Clin Cancer Res* 2006;12:4845–50.
- Taylor KH, Pena-Hernandez KE, Davis JW, et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. *Cancer Res* 2007;67:2617–25.
- Mirebeau D, Acquaviva C, Suci S, et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. *Haematologica* 2006;91:881–5.
- Chim CS, Chan WW, Kwong YL. Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias. *J Clin Pathol* 2008;61:844–7.
- Roman-Gomez J, Castillejo JA, Jimenez A, et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon α. *J Clin Oncol* 2003;21:1472–9.
- Hackanson B, Bennett KL, Brena RM, et al. Epigenetic modification of CCAAT/enhancer binding protein α expression in acute myeloid leukemia. *Cancer Res* 2008;68:3142–51.
- Kim J, Park H, Im JY, Choi WS, Kim HS. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells. *Anticancer Res* 2007;27:3285–92.
- Wang L, Wang J, Blaser BW, et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective

- activity or acquired resistance in acute myeloid leukemia. *Blood* 2007;110:2075–83.
27. Coradini D, Pellizzaro C, Marimpietri D, Abolafio G, Daidone MG. Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. *Cell Prolif* 2000;33:139–46.
28. Muhlethaler-Mottet A, Meier R, Flahaut M, et al. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. *Mol Cancer* 2008;7:55.
29. Baughn LB, Di Liberto M, Wu K, et al. A novel orally active small molecule potently induces G<sub>1</sub> arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. *Cancer Res* 2006;66:7661–7.
30. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. *Cell Cycle* 2006;5:2220–2.
31. Fandy TE, Carraway H, Gore SD. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. *Cancer J* 2007;13:40–8.
32. Roman-Gomez J, Agirre X, Jimenez-Velasco A, et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. *J Clin Oncol* 2009;27:1316–22.
33. Fujimoto T, Anderson K, Jacobsen SE, Nishikawa SI, Nerlov C. Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBP $\alpha$  interaction. *EMBO J* 2007;26:2361–70.
34. Matushansky I, Radparvar F, Skoultschi AI. CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells. *Oncogene* 2003;22:4143–9.
35. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. *Dev Cell* 2006;11:441–50.
36. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. *N Engl J Med* 2008;358:1919–28.
37. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. *JAMA* 2008;299:425–36.
38. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. *Trends Biochem Sci* 2005;30:630–41.
39. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. *Genes Dev* 2004;18:2699–711.
40. Lee YM, Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. *Cell Cycle* 2006;5:2110–4.
41. Sicinska E, Aifantis I, Le Cam L, et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. *Cancer Cell* 2003;4:451–61.
42. Roman-Gomez J, Castillejo JA, Jimenez A, et al. 5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SD1) gene and confers poor prognosis in acute lymphoblastic leukemia. *Blood* 2002;99:2291–6.
43. Menu E, Garcia J, Huang X, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. *Cancer Res* 2008;68:5519–23.
44. Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. *Cell* 2006;125:301–13.
45. Ohm JE, McGarvey KM, Yu X, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. *Nat Genet* 2007;39:237–42.
46. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. *Nat Rev Genet* 2006;7:21–33.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Epigenetic Silencing of the Tumor Suppressor MicroRNA *Hsa-miR-124a* Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia

Xabier Agirre, Amaia Vilas-Zornoza, Antonio Jiménez-Velasco, et al.

*Cancer Res* 2009;69:4443-4453. Published OnlineFirst May 12, 2009.

### Updated version

Access the most recent version of this article at:  
doi:[10.1158/0008-5472.CAN-08-4025](https://doi.org/10.1158/0008-5472.CAN-08-4025)

### Supplementary Material

Access the most recent supplemental material at:  
<http://cancerres.aacrjournals.org/content/suppl/2009/05/04/0008-5472.CAN-08-4025.DC1>

### Cited articles

This article cites 46 articles, 22 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/69/10/4443.full#ref-list-1>

### Citing articles

This article has been cited by 15 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/69/10/4443.full#related-urls>

### E-mail alerts

[Sign up to receive free email-alerts](#) related to this article or journal.

### Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

### Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at [permissions@aacr.org](mailto:permissions@aacr.org).